Physician

Jorge M Chaves, M.D.

According to 2025 Medicare claims, Jorge Chaves, M.D. (NPI: 1265610752) practices hematology/oncology in the Tacoma-Lakewood, WA market, with the plurality of this provider's patient population coming from Pierce, WA. This provider's primary affiliated billing organization is NORTHWEST MEDICAL SPECIALTIES PLLC (NPI: 1548261308; TIN: 911867315) and primary practice location at 98332-5816. Chaves is affiliated with the PSW ACO (ACO ID: A5323), participating under the MSSP model.

Chaves' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 628 traditional Medicare patients, billed 135,302 HCPCS/CPT codes, and received $1,671,040 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,180 prescription claims across 200 beneficiaries totaling $2,027,726 in drug costs, led by Revlimid (Lenalidomide). DME data shows 49 claims. Open Payments data shows 61 records totaling $465,946. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,782,125 and ending at $1,671,040. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $866,536 to $2,027,726. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,737 to $887.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	595	168,435	$1,782,125
2016	635	355,035	$2,088,631
2017	910	371,646	$2,671,502
2018	907	373,992	$3,408,626
2019	800	325,564	$2,661,256
2020	764	225,069	$2,479,665
2021	810	220,208	$3,198,632
2022	718	167,868	$2,365,479
2023	678	162,746	$2,663,266
2024	628	135,302	$1,671,040

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	159	1,186	$866,536
2016	162	1,434	$1,002,698
2017	219	1,580	$924,592
2018	216	1,491	$1,766,293
2019	216	1,620	$2,413,093
2020	180	1,262	$2,806,717
2021	196	1,046	$3,172,645
2022	198	1,205	$3,207,434
2023	200	1,201	$2,517,260
2024	200	1,180	$2,027,726

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	187	$86,946
2016	55	343	$47,696
2017	11	122	$14,490
2018	N/R	80	$9,525
2019	N/R	59	$6,478
2020	N/R	138	$10,565
2021	12	123	$8,762
2022	N/R	66	$2,727
2023	N/R	44	$8,110
2024	N/R	49	$1,583

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	252	474	$98
80053	Blood test, comprehensive group of blood chemicals	335	1,190	$10
36415	Insertion of needle into vein for collection of blood sample	335	1,273	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	324	1,329	$7
83615	Lactate dehydrogenase (enzyme) level	176	495	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	18	483	$348,083
Pomalyst	Pomalidomide	11	308	$273,426
Bosulif	Bosutinib	12	360	$233,428
Lenalidomide	Lenalidomide	21	546	$226,111
Xarelto	Rivaroxaban	65	4,230	$79,253

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$753
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	13	$435
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	21	$395

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	48	$980	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	13	$464,966	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jorge M. Chaves, M.D.?

Tedicare shows public-source Medicare data for Jorge M. Chaves, M.D. (NPI 1265610752), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jorge M. Chaves, M.D. have ACO affiliation data?

Jorge M. Chaves, M.D. is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323).

What billing organization is linked to Jorge M. Chaves, M.D.?

Jorge M. Chaves, M.D. is linked to NORTHWEST MEDICAL SPECIALTIES PLLC (billing NPI 1548261308) in the available physician profile data.

Does Jorge M. Chaves, M.D. have Open Payments data?

Jorge M. Chaves, M.D. has 61 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.